References
- Cohen AS, Franklin EC, Glenner GG. Nomenclature. In: Wegelius O, Pasternack A, eds. Amyloidosis. London: Academic Press; 1976:ix
- Benditt EP, Cohen AS, Costa PP, Franklin EC, Glenner GG, Husby G, Mandema E, et al. Guidelines for nomenclature. In: Glenner GG, Costa PP, Freitas AF, eds. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980:XI–XII
- Husby G, Araki S, Benditt EP, Benson MD, Cohen AS, Frangione B, Glenner GG, et al. The 1990 guidelines for nomenclature and classification of amyloid and amyloidosis. In: Natvig JB, Förre O, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P, eds. Amyloid and amyloidosis 1990. Dordrecht: Kluwer; 1991:7–11
- Westermark P. Classification of amyloid fibril proteins and their precursors: an ongoing discussion. Amyloid 1997;4:216–18
- Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, et al. Amyloid fibril protein nomenclature. Amyloid 2002;9:197–200
- Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S-I, Masters CL, et al. Amyloid: toward terminology classification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005;12:1–4
- Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S-I, Masters CL, et al. A primer of amyloid nomenclature. Amyloid 2007;14:179–83
- Sipe JD, Benson MD, Buxbaum JN, Ikeda S-I, Merlini G, Saraiva MJM, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2012;19:167–70
- Sipe JD, Benson MD, Buxbaum JN, Ikeda S-I, Merlini G, Saraiva MJM, Westermark P. Amyloid fibril protein nomenclature: 2012 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010;17:101–4
- den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Mutat 2000;15:7–12
- Maury CPJ. The emerging concept of functional amyloid (review). J Intern Med 2009;265:329–34
- Münch J, Rucker E, Standker L, Adermann K, Goffinet Ch, Schindler M, Wildum S, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007;131:1059–71
- Usmani SM, Zirafi O, Müller JA, Sandi-Monroy NL, Yadav JK, Meier C, Weil T, et al. Direct visualization of HIV-enhancing endogenous amyloid fibrils in human semen. Nat Commun 2014;5: Article ID:3508
- Kalkunte SS, Neubeck S, Norris WE, Cheng SB, Kostadinov S, Vu Hoang D, Ahmed A, et al. Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model. Am J Pathol 2013;183:1425–36
- WHO-IUIS Nomenclature Sub-Committee. Nomenclature of amyloid and amyloidosis. Bull World Health Organ 1993;71:105–12
- Benson MD, Liepnicks JJ, Kluve-Beckerman B. Hereditary systemic immunoglobulin light-chain (AL) amyloidosis. XIVth Int Symp Amyloidosis, April 27–May 1, 2014, Indianapolis, IN
- Pitkänen P, Westermark P, Cornwell GG III. Senile systemic amyloidosis. Am J Path 1984;117:391–9
- Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843–5
- D'Souza A, Theis JD, Vrana JA, Dogan A. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid 2014;21:71–5